KOD - Kodiak Sciences GAAP EPS of -$1.83 misses by $0.27

Kodiak Sciences press release (NASDAQ:KOD): Q1 GAAP EPS of -$1.83 misses by $0.27. Cash and cash equivalents of $671.7M. "We continued progressing our pipeline product candidates KSI-501 and KSI-601. KSI-501 is our dual inhibitor antibody biopolymer conjugate targeting both VEGF (VEGF-trap) and IL-6 (anti-IL-6 antibody) for the treatment of retinal diseases. We are progressing the bioconjugate cGMP manufacturing, non-clinical toxicology and other supporting activities towards expected IND submission in 2H 2022."

For further details see:

Kodiak Sciences GAAP EPS of -$1.83 misses by $0.27